Form 13-F position report

TRACON PHARMACEUTICALS INC COM

Reported by UBS Group AG

TCON CUSIP 89237H209 Manager CIK 0001610520

First reported at 91,333 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q1 2024
Shares 91,333 Quarter-end amount reported
Reported value $39,273 Fair value at quarter end
Consecutive quarters held 1 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 0
2021-12-31 0
2022-03-31 13000
2022-06-30 0
2022-12-31 1106
2023-03-31 11372
2023-06-30 0
2024-03-31 39273
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

9 quarters
Quarterly reported position history for TRACON PHARMACEUTICALS INC COM held by UBS Group AG.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Reduced 0 -91,333 (-100.0%) 0 $0 2024-08-14
Q1 2024 New 91,333 +91,333 (0.0%) < 0.01% $39,273 2024-05-13
Q2 2023 Reduced 0 -6,017 (-100.0%) 0 $0 2023-08-11
Q1 2023 Added 6,017 +5,275 (710.9%) < 0.01% $11,372 2023-05-12
Q4 2022 New 742 +742 (0.0%) < 0.01% $1,106 2023-02-08
Q2 2022 Reduced 0 -4,828 (-100.0%) 0 $0 2022-08-10
Q1 2022 New 4,828 +4,828 (0.0%) < 0.01% $13,000 2022-05-16
Q4 2021 Reduced 0 -85 (-100.0%) 0 $0 2022-02-14
Q3 2021 Reduced 85 -2,105 (-96.1%) 0 $0 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

36 managers reported TRACON PHARMACEUTICALS INC COM for Q1 2024.

Managers reporting TRACON PHARMACEUTICALS INC COM in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
LPL Financial LLC New 450,650 +450,650 < 0.01% $193,689 1 qtr
ACADIAN ASSET MANAGEMENT LLC Unchanged 413,909 0 < 0.01% $176,000 2 qtrs
Squarepoint Ops LLC Reduced 388,985 -23,286 < 0.01% $167,186 2 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 300,238 +202,200 < 0.01% $129,000 18 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 286,709 +77,923 < 0.01% $123,228 14 qtrs
VANGUARD GROUP INC Unchanged 262,772 0 < 0.01% $112,939 18 qtrs
BlackRock Inc Reduced 260,084 -1,178 < 0.01% $111,784 18 qtrs
JANE STREET GROUP LLC New 182,307 +182,307 < 0.01% $78,356 1 qtr
UBS Group AG This report New 91,333 +91,333 < 0.01% $39,273 1 qtr
JOHNSON & JOHNSON Unchanged 84,003 0 < 0.01% $36,104 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 13, 2024
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
91,333
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.